Kefir-derived exopolysaccharide ameliorates hyperglycemic control and beta cell integrity in a rat model of type 2 diabetes mellitus

• Published in: Nutrition & diabetes Vol. 15; no. 1; pp. 36 - 9
• Main Authors: Yen, Chih-Ching, Tsai, Chung-Liang, Chang, Gary Ro-Lin, Ko, Chi-Hua, Tu, Min-Yu, Lan, Ying-Wei, Chen, Hsiao-Ling, Chen, Chuan-Mu
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 19.08.2025; Nature Publishing Group
• Subjects: 13/51; 631/1647/767/1424; 631/443/319/1642/137/773; 692/699/2743/137/773; 82/51; 82/80; 96/95; Animals; Antibodies; Blood Glucose - drug effects; Blood Glucose - metabolism; Cholesterol; Clinical Nutrition; Diabetes; Diabetes Mellitus, Experimental - drug therapy; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Diet; Diet, High-Fat - adverse effects; Epidemiology; Fermentation; Glucose; Glucose Transporter Type 2 - metabolism; High density lipoprotein; Hyperglycemia - drug therapy; Insulin - blood; Insulin resistance; Insulin-Secreting Cells - drug effects; Insulin-Secreting Cells - metabolism; Internal Medicine; Kefir; Kidneys; Kinases; Laboratories; Lipoproteins; Liver - drug effects; Liver - metabolism; Male; Medicine; Medicine & Public Health; Metabolic Diseases; Molecular weight; Polysaccharides - pharmacology; Polysaccharides - therapeutic use; Rats; Rats, Sprague-Dawley; Streptozocin; United States > US; Taiwan

Objective Diabetes mellitus (DM) is a chronic metabolic disorder characterized by elevated blood glucose levels due to insulin deficiency or resistance. While conventional treatments are effective, integrating nutraceuticals that aid in blood sugar control is crucial for patients with low compliance...